Skip to content

Advertisement

  • Poster presentation
  • Open Access

Activation of innate and adaptive immunity as an effective combined strategy for cancer immunotherapy

  • Alexander Rakhmilevich1,
  • Mildred Felder1,
  • Lauren Lever1,
  • Tyler Van De Voort1,
  • Alan J Korman2,
  • Stephen D Gillies3 and
  • Paul M Sondel4
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P370

https://doi.org/10.1186/2051-1426-3-S2-P370

Published: 4 November 2015

Keywords

Antitumor EffectAdaptive ImmunityDrain Lymph NodeCancer ImmunotherapyIntratumoral Injection

Immunotherapeutic approaches can demonstrate some antitumor benefit, but their efficacy is limited when they are used as a single modality. We asked if a combinatory approach activating both innate and adaptive immunity would improve cancer immunotherapy. We have previously shown that an agonistic anti-CD40 monoclonal antibody (anti-CD40) in combination with a toll-like receptor 9 agonist, CpG, can activate macrophages in mice, leading to tumor cell killing. Separately, we have shown that a direct intratumoral injection of an immunocytokine (IC) consisting of anti-GD2 antibody linked to interleukin-2 can activate NK and T cells, resulting in antitumor effects. We hypothesize that activation of macrophages (with anti-CD40/CpG) and NK cells (with IC) will increase tumor destruction and presentation of tumor antigens, leading to T cell activation, which in turn could be further augmented by anti-CTLA-4 antibody, resulting in tumor eradication and prevention of tumor recurrence. Using the mouse GD2+ B78 melanoma model, we show that anti-CD40/CpG and IC/anti-CTLA-4 synergistically induced regression of established subcutaneous tumors, resulting in the cure of 50% of mice and development of immunological memory against B78 as well as wild type B16 tumors. While the antitumor effect of anti-CD40/CpG was T cell independent, the antitumor effect of IC/anti-CTLA-4 required T cells. Anti-CD40/CpG treatment led to upregulation of T cell activation markers in draining lymph nodes. Finally, the combined treatment with anti-CD40/CpG and IC/anti-CTLA-4 was effective against B16 lung metastases. We suggest that a combination of anti-CD40/CpG and IC/anti-CTLA-4 should be tested as a clinically relevant novel treatment strategy.

Authors’ Affiliations

(1)
UW-Madison, Madison, USA
(2)
Bristol-Myers Squibb Company, Redwood City, USA
(3)
Provenance Biopharmaceuticals, Carlisle, USA
(4)
Department of Human Oncology, Department of Pediatrics, University of Wisconsin-Madison, Madison, USA

Copyright

© Rakhmilevich et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement